Fig. 6: circCNOT6L inhibits cellular ferroptosis via the SRSF2–SLC7A11 axis and promotes malignant progression in PCa. | Experimental & Molecular Medicine

Fig. 6: circCNOT6L inhibits cellular ferroptosis via the SRSF2–SLC7A11 axis and promotes malignant progression in PCa.

From: CircCNOT6L modulates alternative splicing of SLC7A11 via splicing factor SRSF2 to confer ferroptosis resistance and promote metastasis in prostate cancer

Fig. 6

a Western blotting reveals regulatory relationships between circCNOT6L, SRSF2 and SLC7A11. b Lipid ROS changes assessed by confocal using the C11 probe after treatment of cells with oe-circCNOT6L and si-SRSF2. c–e Following treatment with oe-circCNOT6L, si-SRSF2 and erastin (5 μM), the distribution of Fe²⁺ in PC3 and LNCaP cells was visualized using confocal microscopy with fluorescent probes. f–h PC3 and DU145 were treated with oe-circCNOT6L, si-SRSF2 and erastin (5 μM), and cellular GSH content was measured using a GSH assay kit and zymography. i, j Changes in cell-invasion ability were assessed using a 3D Matrigel drop invasion assay following treatment of PC3 and DU145 cells with oe-circCNOT6L, si-SRSF2 and erastin (5 μM). k, l Changes in cell-migration ability were assessed using a transwell assay following treatment of PC3 and DU145 cells with oe-circCNOT6L, si-SRSF2 and erastin (5 μM).

Back to article page